To ban, or not to ban, was the question at the spring meeting at which members of an advisory panel of the Food and Drug Administration (FDA) recommended that the agency should prohibit the use of class II electrical stimulation devices (ESDs) for aversive conditioning therapy in patients with nonsuicidal self-injuries or aggressive behaviors.

The decision was made after the majority of the members of the Neurological Devices Panel agreed that based on available data and information, the devices pose “an unreasonable and substantial risk of illness or injury” to patients. 

READ FULL ARTICLE Curated publisher From